Arbutus Biopharma Corporation · NASDAQ:ABUS
Androski Lindsay exercised options for 126,864 Arbutus Biopharma Corporation shares (Form 4)
Traded Sep 18, 2026 · Filed Sep 23, 2026
On Sep 18, 2026, Androski Lindsay (Director, President and CEO) exercised options for 126,864 Arbutus Biopharma Corporation shares at an average US$3.30 for US$418K, leaving 72,337 shares. Filed Sep 23, 2026 (Form 4).
- Options exercised
- 126,864 shares
- Price
- US$3.30 average (US$3.20 to US$4.39)
- Value
- US$418K
- Holding after
- 72,337 shares
- Trading plan
- No
- Role
- Director, President and CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Common Shares | Option exercise | 116,408 | US$3.20 | 144,408 | Direct |
| Sep 18, 2026 | Common Shares | Option exercise | 10,456 | US$4.39 | 154,864 | Direct |
| Sep 18, 2026 | Common Shares | Shares withheld for tax | 82,527 | US$5.07 | 72,337 | Direct |
Source
Related
- Arbutus Biopharma Corporation
- Androski Lindsay
- Arbutus Biopharma Corporation shareholders
- Form 4 · Androski Lindsay · Oct 7, 2026
- Form 4 · Sawhney Roger · Oct 7, 2026
- Form 4 · Nguyen Tuan · Oct 7, 2026
- Form 4 · Beardsley Robert A · Oct 7, 2026
- Schedule 13G/A · Morgan Stanley · Oct 7, 2026
- Schedule 13D/A · Roivant Sciences Ltd. · Oct 5, 2026